Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

  • Showing results for a modified search because your search retrieved no results.
  • The following term was ignored: OR
  • See the search details.
1.

MR-based age-related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan.

Tullo S, Patel R, Devenyi GA, Salaciak A, Bedford SA, Farzin S, Wlodarski N, Tardif CL; PREVENT-AD Research Group, Breitner JCS, Chakravarty MM.

Hum Brain Mapp. 2019 Aug 26. doi: 10.1002/hbm.24771. [Epub ahead of print]

PMID:
31452289
2.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.

Picard C, Poirier A, Bélanger S, Labonté A, Auld D, Poirier J; PREVENT-AD Research Group.

PLoS One. 2019 Aug 22;14(8):e0220254. doi: 10.1371/journal.pone.0220254. eCollection 2019.

3.

Association of PPP2R1A with Alzheimer's disease and specific cognitive domains.

Miron J, Picard C, Labonté A, Auld D, Breitner J, Poirier J; United Kingdom Brain Expression Consortium; PREVENT-AD research group.

Neurobiol Aging. 2019 Sep;81:234-243. doi: 10.1016/j.neurobiolaging.2019.06.008. Epub 2019 Jul 2.

PMID:
31349112
4.

No apparent effect of naproxen on CSF markers of innate immune activation.

Meyer PF, Labonté A, Rosa-Neto P, Poirier J, Breitner JCS; PREVENT‐AD Research Group.

Ann Clin Transl Neurol. 2019 Jun 6;6(6):1127-1133. doi: 10.1002/acn3.788. eCollection 2019 Jun.

5.

Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.

Miron J, Picard C, Lafaille-Magnan MÉ, Savard M, Labonté A, Breitner J, Rosa-Neto P, Auld D, Poirier J; PREVENT-AD research group.

Alzheimers Dement. 2019 Jul;15(7):951-960. doi: 10.1016/j.jalz.2019.03.012. Epub 2019 Jun 4.

PMID:
31175027
6.

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.

Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan MÉ, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner J; PREVENT-AD Research Group.

Neurology. 2019 Apr 30;92(18):e2070-e2080. doi: 10.1212/WNL.0000000000007232. Epub 2019 Apr 5. Erratum in: Neurology. 2019 Aug 20;93(8):371.

7.

Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease.

Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14.

PMID:
29735156
8.

Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.

Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative* and the PREVENT-AD Research Group.

Brain. 2018 Jun 1;141(6):1871-1883. doi: 10.1093/brain/awy093.

9.

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.

Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.

J Alzheimers Dis. 2018;63(2):577-590. doi: 10.3233/JAD-170887.

10.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

11.

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.

Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner J, Chakravarty MM; PREVENT-AD Research Group.

Hum Brain Mapp. 2018 Feb;39(2):971-984. doi: 10.1002/hbm.23897. Epub 2017 Nov 21.

PMID:
29164798
12.

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.

Tuwaig M, Savard M, Jutras B, Poirier J, Collins DL, Rosa-Neto P, Fontaine D, Breitner JCS; PREVENT-AD Research Group.

J Alzheimers Dis. 2017;60(4):1589-1600. doi: 10.3233/JAD-170545.

13.

Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group.

Neurology. 2017 Jul 25;89(4):327-335. doi: 10.1212/WNL.0000000000004159. Epub 2017 Jun 28.

14.

Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease.

Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JC, Bellec P; PREVENT-AD Research Group.

Sci Data. 2015 Oct 13;2:150043. doi: 10.1038/sdata.2015.43. eCollection 2015.

Supplemental Content

Loading ...
Support Center